|
Tim Marlowe, PhD |
 |
Brief Bio
Dr. Marlowe directs a drug discovery laboratory at the University of Arizona College of Medicine – Phoenix, Cancer Center and College of Pharmacy. Dr. Marlowe's laboratory primarily investigates the cancer drug target focal adhesion kinase (FAK) and the mechanisms by which cancer and fibrotic disorders depend on FAK signaling for disease progression. He is chief scientific officer of biotech company FAKnostics, LLC, focused on FAK diagnostics & therapeutics. He is also director of the Molecular Discovery Core (MDC) facility, accelerating the development of drugs and chemical probes against multiple targets.
Dr. Marlowe received his PhD in Molecular Pharmacology and Cancer Therapeutics from Roswell Park Cancer Institute and BS in Pharmacology and Toxicology from the State University of New York at Buffalo.
Dr. Marlowe has a strong background in pharmacology and drug discovery, with major expertise in structure-based drug design, computational drug discovery, and a wide variety of biophysical and biochemical assays. His research is focused on:
- Structure-based discovery of novel FAK inhibitors.
- Synthesis of peptides and small molecules.
- Biological mechanisms of the FAK pathway in both cancer and fibrosis.
- Drug discovery technology (SPR, NMR, fragment screening, X-ray crystallography).
Most recently, his lab has identified a series of cyclic peptide-based drug candidates that inactivate the focal adhesion targeting (FAT) domain, the protein domain of FAK that regulates the focal adhesion complex and FAK localization. These promising molecules have shown significant efficacy in pre-clinical models of melanoma, liver fibrosis and lung fibrosis; and are under current drug development studies.